Theravance Biopharma Inc. (NASDAQ:TBPH) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $28.75 and last traded at $27.91, with a volume of 68,415 shares traded. The stock had previously closed at $28.17.

A number of equities research analysts recently issued reports on the stock. Leerink Swann reiterated a “buy” rating on shares of Theravance Biopharma in a report on Saturday, June 4th. Bank of America Corp. cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Tuesday, July 12th. Finally, Guggenheim assumed coverage on shares of Theravance Biopharma in a report on Monday, June 20th. They issued a “buy” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Theravance Biopharma presently has a consensus rating of “Hold” and an average target price of $29.00.

The stock’s market capitalization is $1.34 billion. The stock’s 50 day moving average price is $25.15 and its 200-day moving average price is $21.28.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.01. On average, equities analysts predict that Theravance Biopharma Inc. will post ($4.03) EPS for the current fiscal year.

In other Theravance Biopharma news, SVP Brett K. Haumann sold 4,491 shares of the stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $27.99, for a total value of $125,703.09. Following the sale, the senior vice president now directly owns 188,293 shares in the company, valued at $5,270,321.07. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Bradford J. Shafer sold 49,122 shares of the stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the completion of the sale, the executive vice president now owns 241,686 shares in the company, valued at $6,636,697.56. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.